Objective
=========

We hypothesized that changes in atherosclerotic plaque composition with lipid lowering therapy could be measured in patients with peripheral arterial disease (PAD) using MRI of the superficial femoral artery (SFA).

Background
==========

MRI of atherosclerotic plaque components in the carotid arteries correlates with histology, is reproducible, and can monitor lipid lowering therapy.

Methods
=======

43 patients with PAD (age 63±9, ABI 0.72±0.14) were imaged at baseline and annually for 2 years after beginning lipid lowering therapy. Twenty statin-naïve patients were randomized to simvastatin (S, n=11) or simvastatin+ezetimibe (S+E, n=9). Patients already on statins not at LDL cholesterol goal had open-label ezetimibe added (E, n=23). MRI of a single slice of the SFA was performed on Siemens Avanto 1.5T scanner with a proton-density weighted image (TR 1100ms, TE 7.6ms), T1-W image (TR 700ms, TE 7.7ms) and T2-W image (TR 2000ms, TE 85ms), using slice thickness 3mm, matrix 256x256 pixels, FOV 150mm, flip angle 180°. Image location was repeated over time using the distance of the imaged slice from the bifurcation of the common femoral artery. Image quality scale from 1-4 was used to grade the images, excluding 6 studies for score ≤ 2 in more than one image. VesselMASS software was used to measure plaque components (lipids, calcium, loose matrix and fibrous tissue) based on published critieria for appearance on T1/T2/PDW images. Changes in parameters were assessed with ANOVA repeated measures model and correlation with two-tailed Pearson.

Results
=======

LDL at baseline in the statin-naïve patients (S and S+E) was 127±34mg/dl and fell at one year (82±37, p\<0.001) and was unchanged at two years (84±44). There was no difference in LDL between S and S+E. The LDL in E at baseline was 93±21mg/dl, decreased significantly at one year (77±35, p\<0.001), and was similar at year 2 (74±27). Total cholesterol changes paralleled that of LDL. See Table [1](#T1){ref-type="table"} for changes in wall area and plaque components. The amount of plaque lipids correlated with wall area (r=0.44, p\<0.003) for for all studies. Intra-observer variability examined in 10 patients with an intra-class correlation coefficient of 0.99 for wall area and 0.88 for plaque components.

###### 

Changes in plaque over time

                                   Baseline      Year 1        Year 2
  -------------------------------- ------------- ------------- -------------
  **Wall Area (cm^2^)**                                        
  S and S+E                        0.33±0.14     0.32±0.14     0.32±0.14
  E                                0.31±0.05     0.29±0.12     0.29±0.12
  **Lipids (cm^2^)**                                           
  S and S+E                        0.05±0.04     0.04±0.04     0.03±0.03\*
  E                                0.04±0.05     0.04±0.05     0.02±0.03\*
  **Calcium (cm^2^)**                                          
  S and S+E                        0.004±0.007   0.005±0.010   0.009±0.016
  E                                0.011±0.026   0.011±0.022   0.014±0.023
  **Loose Matrix(cm^2^)**                                      
  S and S+E                        0.05±0.07     0.04±0.05     0.03±0.03
  E                                0.03±0.06     0.04±0.07     0.04±0.07
  **Fibrous** Tissue **(cm^2^)**                               
  S and S+E                        0.23±0.13     0.23±0.12     0.25±0.13
  E                                0.23±0.09     0.20±0.10     0.22±0.10

\*ANOVA p\<0.05

Conclusion
==========

LDL lowering therapy over 2 years decreases plaque lipids without a significant change in plaque area or other components as demonstrated by MRI.
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